Beta Cell Biomarker Imaging for Non-Invasive Diabetes Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for imaging and quantifying pancreatic beta cell mass in diabetes are inadequate, as they rely on invasive procedures and lack specificity, making it difficult to accurately follow beta cell mass in diabetic patients and predict disease progression or response to therapies.
Innovation Solution
A biomarker specifically expressed on beta cells, such as DPP6, is used for non-invasive imaging and targeting strategies, allowing for the visualization and quantification of beta cell mass through labeled antibodies or peptides, enabling early identification of beta cell mass variations and monitoring of diabetes therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive procedures are used to determine beta cell mass, then measurement precision may be improved, but ease of operation deteriorates and loss of time increases
Solution Approach 1:
The patent replaces invasive mechanical/biological procedures (pancreatectomy, autopsy, biopsy) with non-invasive molecular imaging techniques. Radioligands bind to beta-cell-specific biomarkers and are detected by imaging modalities (PET, SPECT, MRI), eliminating the need for tissue removal while maintaining measurement capability.
Solution Approach 2:
The patent introduces radioligands as intermediary molecules that specifically bind to beta-cell biomarkers. These radioligands serve as mediators between the imaging system and beta cells, enabling indirect detection of beta cell mass without direct tissue sampling.
2Ease of operation
If general imaging methods are used, then ease of operation is maintained, but measurement precision of beta cell mass deteriorates
Solution Approach 1:
The patent applies local quality by using radioligands with high specificity for beta-cell biomarkers. The radioligands concentrate specifically in beta cells rather than distributing uniformly, enabling precise localization and quantification of beta cell mass within the pancreas while maintaining ease of whole-body imaging.
Solution Approach 2:
The patent uses radioligands labeled with radioactive isotopes or contrast agents that produce detectable signals (analogous to color changes). The signal intensity correlates with beta cell mass, allowing precise quantification through standard imaging modalities without requiring specialized equipment.
3Device complexity
If current imaging methods are used, then device complexity is minimized, but reliability of beta cell mass determination deteriorates
Solution Approach 1:
The patent changes the biochemical parameter being measured by targeting specific beta-cell biomarkers (e.g., synaptotagmin, chromogranin) rather than using non-specific tracers. This biomarker-specific approach increases reliability of beta cell mass determination while using standard imaging equipment, without requiring complex new devices.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early prediction and intervention in diabetes, allows for the follow-up of beta cell mass after islet transplantation, and provides a non-invasive method for diagnosing and monitoring diabetic disorders by detecting beta cell mass, potentially leading to better treatment strategies.
Implementation Method 1
A biomarker specifically expressed on beta cells, such as DPP6, is used for non-invasive imaging and targeting strategies, allowing for the visualization and quantification of beta cell mass through labeled antibodies or peptides
Data Source
Figure 1
Figure 2~3
Figure 4A~4B
AI summary
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).